Relay Therapeutics
RLAY
132 hedge funds and large institutions have $2.89B invested in Relay Therapeutics in 2021 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 55 increasing their positions, 30 reducing their positions, and 14 closing their positions.
83% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 30
50% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 14
36% more call options, than puts
Call options by funds: $6.87M | Put options by funds: $5.04M
6% more funds holding
Funds holding: 125 → 132 (+7)
0.41% more ownership
Funds ownership: 98.6% → 99.01% (+0.41%)
11% less capital invested
Capital invested by funds: $3.26B → $2.89B (-$367M)
50% less funds holding in top 10
Funds holding in top 10: 8 → 4 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$112M |
| 2 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$37.5M |
| 3 |
BlackRock
New York
|
+$27.3M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$19.9M |
| 5 |
State Street
Boston,
Massachusetts
|
+$15.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$104M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$29.9M |
| 3 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$20.4M |
| 4 |
FCMV
Foresite Capital Management V
Larkspur,
California
|
-$14.6M |
| 5 |
O
OrbiMed
New York
|
-$12.8M |
RLAY Hedge Fund Activity: Q3 2021 in Review
132 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Relay Therapeutics (RLAY) for Q3 2021, worth a combined $2.89B — down 11% from $3.26B a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new RLAY positions and 14 closed out — a net gain of 7 holders — while 55 added to existing stakes and 30 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $112M. The largest seller was EcoR1 Capital, cutting an estimated $104M.
- 132 institutional investors held Relay Therapeutics (RLAY) as of Q3 2021, up from 125 in Q2 2021.
- Funds reported $2.89B of Relay Therapeutics stock for Q3 2021, down 11% quarter-over-quarter.
- 21 funds opened new Relay Therapeutics positions in Q3 2021 and 14 closed out, a net change of +7 holders.
- The largest Relay Therapeutics buyer in Q3 2021 was Fidelity Investments, an estimated $112M added.
- The largest Relay Therapeutics seller in Q3 2021 was EcoR1 Capital, an estimated $104M sold.
Based on aggregated 13F filings for Q3 2021.